Contact person: Phyllis D. Artis, Parklawn, Room 9C–26, 5600 Fishers Lane, Rockville, MD 20857, Telephone: 301, 443–6470.

Committee Name: Health Behavior and Prevention Review Committee.

Date: June 17, 1998. Time: 8:30 a.m.

Place: One Washington Circle, One Washington Circle, N.W., Washington, DC 20037.

Contact person: Monica F. Woodfork, Parklawn, Room 9C–26, 5600 Fishers Lane, Rockville, MD 20857, Telephone: 301, 443– 6470.

Committee Name: Perception and Cognition Review Committee.

Date: June 18-June 19, 1998.

Time: 8:30 a.m.

Place: One Washington Circle, One Washington Circle, N.W., Washington, DC 20047.

Contact Person: Deborah A. DeMasse, Parklawn, Room 9–101, 5600 Fishers Lane, Rockville, MD 20857, Telephone: 301, 443– 3936

Committee Name: Social and Group Processes Review Committee.

Date: June 18-June 19, 1998.

Time: 8 a.m.

Place: Bethesda Holiday Inn, 8120 Wisconsin Avenue, Bethesda, MD 20814.

Contact Person: Tarsha Johnson, Parklawn, Room 9–101, 5600 Fishers Lane, Rockville, MD 20857, Telephone: 301, 443–64700.

Committee Name: Clinical Centers and Special Projects Review Committee.

Date: June 25-June 26, 1998.

Time: 8:30 a.m.

Place: Bethesda Holiday Inn, 8120 Wisconsin Avenue, Bethesda, MD 20814.

Contact Person: W. Gregory Zimmerman, Parklawn, Room 9C–18, 5600 Fishers Lane, Rockville, MD 20857 Telephone: 301, 443– 1340

Committee Name: Mental Disorders of Aging Review Committee.

Date: June 25-June 26, 1998.

Time: 8:30 a.m.

Place: Holiday Inn Chevy Chase, 5520 Wisconsin Ave, Chevy Chase, MD 20815.

Contact Person: Henry Haigler, Parklawn, Room 9C–18, 5600 Fishers Lane, Rockville, MD 20857, Telephone: 301, 443–1340.

The meeting will be closed in accordance with the provisions set forth in secs. 552b(2)(4) and 552b(c)(6), Title 5, U.S.C. Applications and/or proposals and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications and/or proposals, the disclosure of which would constitute a clearly unwarranted invasions of personal privacy. (Catalog of Federal Domestic Assistance Program Numbers 93.242, 93.281, 93.282)

Dated: May 6, 1998.

LaVerne Y. Stringfield,

Committee Management Officer, NIH. [FR Doc. 98–12773 Filed 5–13–98; 8:45 am] BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Nursing Research; Notice of Closed Meetings

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meetings:

Name of Committee: National Institute of Nursing Research Initial Review Group.

Date: June 22–23, 1998.

Time: 8:30 a.m. until adjournment.

Place: Holiday Inn Chevy Chase, 5520 Wisconsin Avenue, Chevy Chase, Maryland 20815.

Contact Person: Mary Stephens-Frazier, Ph.D., Building 45, Room 3AN–28, 45 Center Drive, Bethesda, MD 20892, (301) 594–5971.

Purpose/Agenda: To review and evaluate grant applications.

Name of Committee: National Institute of Nursing Research Special Emphasis Panel (NINR/ORMH Mentored Research Scientist Development Award for Minority Investigators.

Date: June 24, 1998.

Time: 8:30 a.m.

Place: Holiday Inn Chevy Chase, 5520 Wisconsin Avenue, Chevy Chase, Maryland 20815.

Contact Person: Mary Stephens-Frazier, Ph.D., Building 45, Room 3AN-18, 45 Center Drive, Bethesda, MD 20892, (301) 594-5971.

Purpose/Agenda: To review and evaluate grant applications.

These meetings will be closed in accordance with the provisions set forth in secs. 552b(c)(4) and 552b(c)(6), title 5, U.S.C. Applications and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

(Catalog of Federal Domestic Assistance Program No. 93.361, Nursing Research, National Institutes of Health)

Dated: May 7, 1998.

LaVerne Y. Stringfield,

Committee Management Officer, NIH. [FR Doc. 98–12775 Filed 5–13–98; 8:45 am] BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Center for Scientific Review; Notice of Closed Meetings

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following Center for Scientific Review Special Emphasis Panel (SEP) meetings:

Purpose/Agenda: To review individual grant applications.

Name of SEP: Clinical Sciences.

Date: May 12, 1998.

Time: 1:00 p.m.

Place: NIH, Rockledge 2, Room 4114, Telephone Conference.

Contact Person: Dr. Scott Osborne, Scientific Review Administrator, 6701 Rockledge Drive, Room 4114, Bethesda, Maryland 20892, (301) 435–1782.

Name of SEP: Clinical Sciences.

Date: May 13, 1998.

Time: 1:00 p.m.

Place: NIH, Rockledge 2, Room 4114, Telephone Conference.

Contact Person: Dr. Scott Osborne, Scientific Review Administrator, 6701 Rockledge Drive, Room 4114, Bethesda, Maryland 20892, (301) 435–1782.

Name of SEP: Clinical Sciences.

Date: May 18, 1998.

Time: 1:00 p.m.

Place: NIH, Rockledge 2, Room 4114, Telephone Conference.

Contact Person: Dr. Scott Osborne, Scientific Review Administrator, 6701 Rockledge Drive, Room 4114, Bethesda, Maryland 20892, (301) 435–1782.

This notice is being published less than 15 days prior to the above meetings due to the urgent need to meet timing limitations imposed by the grant review and funding cycle.

The meetings will be closed in accordance with the provisions set forth in secs. 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. Applicants and/or proposals and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications and/or proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. (Catalog of Federal Domestic Assistance Program Nos. 93.306, 93.333, 93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 83,893, National Institutes of Health, HHS)

Dated: May 7, 1998.

LaVerne Y. Stringfield,

Committee Management Officer, NIH. [FR Doc. 98–12777 Filed 5–13–98; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Public Health Service

National Toxicology Program; Availability of the Report on Carcinogens, Eighth Edition

Background

The National Toxicology Program (NTP) announces the availability of the Report on Carcinogens, Eighth Edition.

The Report on Carcinogens (RoC) is a Congressionally-mandated listing of known human carcinogens and reasonably anticipated human carcinogens and its preparation is delegated to the National Toxicology Program by the Secretary, Department of Health and Human Services (HHS) Section 301(b)(4) of the Public Health Service Act, as amended, provides that the Secretary, (HHS), shall publish a report which contains a list of all substances (1) which either are known to be human carcinogens or may reasonably be anticipated to be human carcinogens; and (2) to which a significant number of persons residing in the United States (US) are exposed. The law also states that the reports should provide available information on the nature of exposures, the estimated number of persons exposed and the extent to which the implementation of Federal regulations decreases the risk to public health from exposure to these chemicals.

The new entries for the 8th RoC have undergone a multiphased peer review process involving two Federal scientific review groups and one non-government, scientific peer review body (a subcommittee of the NTP Board of Scientific Counselors) which met in an open, public meeting that included a public comment session. All data relevant to the criteria for inclusion of candidate agents, substances or mixtures in the RoC have been evaluated by the three scientific review committees.

In the 8th RoC, the NTP is adding 14 agents, substances or mixtures to the existing list. In addition, thiotepa, which is currently listed in previous Reports on Carcinogens as reasonably anticipated to be a human carcinogen is moved to the known human carcinogen list. These agents, substances or mixtures are provided in the following table with their Chemical Abstracts Services (CAS) Registry numbers and listing.

Hard copies of the 8th RoC, or the 8th RoC Summary (which contains the same

information that is in the full Report with the exception of specific information on regulations promulgated by regulatory health agencies) can be obtained by contacting the NIEHS **Environmental Health Information** Service, ATTN: Order Processing, P.O. Box 12510, Research Triangle Park, NC 27709-2510, fax number (919) 541-0763, email: ehis@niehs.nih.gov. The 8th RoC Summary is also available on the internet and can be accessed from the NIEHS Environmental Health Information Service Home Page at: http:///ehis.niehs.nih.gov/ or from the NTP Home Page at: http://ntpserver.niehs.nih.gov//.

Questions or comments concerning the 8th RoC should be directed to: Dr. C.W. Jameson, National Toxicology Program, Report on Carcinogens, MD EC-14, P.O. Box 12233, Research Triangle Park, NC 27709; phone: (919) 541-4096, fax: (919) 541-2242, email: jameson@niehs.nih.gov.

Kenneth Olden,

Director, National Toxicology Program.

SUMMARY FOR AGENTS, SUBSTANCES OR MIXTURES NEWLY LISTED IN THE REPORT ON CARCINOGENS, EIGHTH EDITION

,		•			
Chemical/CAS number	Primary uses	Newly listed as			_
AZACITIDINE/320-67-2	Used as a cytostatic agent in the treatment of acute leukemia	Reasonably Anticipated Human Carcinogen	to	be	а
p-CHLORO-o-TOLUIDINE and its HCl salt/95-69-2.	Used to produce azo dyes for cotton, silk acetate and nylon and as intermediate in production of Pigment Red 7 and Pigment Yellow 49. Also an impurity in and a metabolite of the pesticide chlordimeform.	Reasonably Anticipated Human Carcinogen.	to	be	а
CHLOROZOTOCIN/54749-90-5	Used as a cytostatic agent in the treatment of cancers of the stomach, large intestine pancreas and lung; melanoma; and multiple myeloma.	Reasonably Anticipated Human Carcinogen.	to	be	а
CYCLOSPORIN/59865-13-3	Used as an immunosuppressive agent in the prevention and treatment of graft-vs-host reactions in bone marrow transplantation and for the prevention of rejection of kidney, heart, and liver transplants.	Known to be a Human gen.	Ca	arcin	0-
DANTHRON/(1,8- Dihydroxyanthraquinone) 117- 10-2.	Used as a laxative and as an intermediate in the manufacture of dyes	Reasonably Anticipated Human Carcinogen	to	be	а
1,6-DINITROPYRENE/42397-64-8	Not used commercially, detected in ambient atmospheric samples and as a constituent of diesel exhaust.	Reasonably Anticipated Human Carcinogen	to	be	а
1,8-DINITROPYRENE/42397-65-9	Not used commercially, detected in ambient atmospheric samples and as a constituent of diesel exhaust.	Reasonably Anticipated Human Carcinogen			
DISPERSE BLUE 1/(1,4,5,8- Tetraaminoanthraquinone) 2475- 45-8.	Used as an anthraquinone based dyestuff in hair color formulations and in coloring fabrics and plastics.	Reasonably Anticipated Human Carcinogen	to	be	а
FURAN/100-00-9	Used as an intermediate in the synthesis and production of other organic compounds.	Reasonably Anticipated Human Carcinogen	to	be	а
O-NITROANISOLE/91-23-6	Used a a precursor in the synthesis of o-anisidine which is used in the manufacture of over 100 azo dyes.	Reasonably Anticipated Human Carcinogen.	to	be	а
6-NITROCHRYSENE/7495-02-8	Not used commercially, detected in ambient atmospheric samples	Reasonably Anticipated Human Carcinogen.	to	be	а
1-NITROPYRENE/5522-43-0	Not used commercially, detected in ambient atmospheric samples and as a constituent of diesel and gasoline engine exhaust.	Reasonably Anticipated Human Carcinogen.	to	be	а
4-NITROPYRENE/57835-92-4	Not used commercially, detected in ambient atmospheric samples	Reasonably Anticipated Human Carcinogen.	to	be	а
THIOTEPA/52-24-4	Used as a cytostatic agent in the treatment of lymphomas and a variety of solid tumors, such as breast and ovary. It has also been used at high doses in combination chemotherapy with cyclophosphamide in patients with refractory malignancies treated	Known to be a Human gen.	Ca	arcin	0-

with autologous bone transplantation.

SUMMARY FOR AGENTS, SUBSTANCES OR MIXTURES NEWLY LISTED IN THE REPORT ON CARCINOGENS, EIGHTH EDITION—Continued

Chemical/CAS number	Primary uses	Newly listed as	
1,2,3-TRICHLOROPROPANE/96- 18-4.	Used as a polymer crosslinking agent, paint and varnish remover, solvent and degreasing agent. It has been found as an impurity in certain nematicides and soil fumigants and has been detected in drinking and ground water in various parts of the United States.	Human Ćarcinogen.	

[FR Doc. 98–12779 Filed 5–13–98; 8:45 am] BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Substance Abuse and Mental Health Services Administration Agency Information Collection Activities: Submission for OMB Review; Comment Request

Periodically, the Substance Abuse and Mental Health Services Administration (SAMHSA) will publish a list of information collection requests under OMB review, in compliance with the Paperwork Reduction Act (44 U.S.C. Chapter 35). To request a copy of these documents, call the SAMHSA Reports Clearance Officer on (301) 443–7978.

Community Mental Health Centers (CMHC) Construction Grantee Checklist—0930–0104—Extension, no change—Recipients of Federal CMHC construction funds are obligated to use the constructed facilities to provide mental health services. The CMHS Act

was repealed in 1981 except for the provision requiring grantees to continue using the facilities for mental health purposes for a 20-year period. In order for the Center for Mental Health Services to monitor compliance of construction grantees the grantees are required to submit an annual report. The Checklist enables grantees to supply necessary information efficiently and with a minimum of burden.

	Annual re- spondents	Responses/ respondent	Hours per response	Annual bur- den
CMHS Grantee Construction Checklist [42 CFR 54.209(h), 42 CFR 54.213, 42 CFR 54.214]	* 68	1	.33	22

^{*} Average over the 3-year approval period as grantees with service obligations continue to complete their period of obligation.

Written comments and recommendations concerning the proposed information collection should be sent within 30 days of this notice to: Daniel Chenok, Human Resources and Housing Branch, Office of Management and Budget, New Executive Office Building, Room 10235, Washington, D.C. 20503.

Dated: May 7, 1998.

Richard Kopanda,

Executive Officer, SAMHSA.

[FR Doc. 98-12824 Filed 5-13-98; 8:45 am]

BILLING CODE 4162-20-P

DEPARTMENT OF THE INTERIOR

Fish and Wildlife Service

Endangered and Threatened Species Permit Applications

AGENCY: Fish and Wildlife Service, Interior.

ACTION: Notice of receipt of applications.

The following applicants have applied for permits to conduct certain activities with endangered species. This notice is provided pursuant to section 10(c) of the Endangered Species Act of 1973, as amended (16 U.S.C. 1531, et seq.).

Applicant: The Raptor Resource Project, Ridgeway, Iowa; Robert Anderson, Director.

The applicant requests a permit to take (capture, handle, draw blood, and release) peregrine falcon (*Falco peregrinus*) in the states of Iowa, Minnesota, and Wisconsin. Activities are proposed for the purpose of scientific research aimed at enhancement and survival of the species in the wild.

Written data or comments should be submitted to the Regional Director, U.S. Fish and Wildlife Service, Ecological Services Operations, 1 Federal Drive, Fort Snelling, Minnesota 55111–4056, and must be received within 30 days of the date of this publication.

Documents and other information submitted with these applications are available for review by any party who submits a written request for a copy of such documents to the following office within 30 days of the date of publication of this notice: U.S. Fish and Wildlife Service, Ecological Services Operations, 1 Federal Drive, Fort Snelling, Minnesota 55111-4056. Telephone: (612/713–5332); FAX: (612/713–5292).

Dated: May 7, 1998.

Matthias A. Kerschbaum,

Acting Assistant Regional Director, IL, IN, MO (Ecological Services), Region 3, Fort Snelling, Minnesota.

[FR Doc. 98–12804 Filed 5–13–98; 8:45 am] BILLING CODE 4310–55–P

DEPARTMENT OF THE INTERIOR

Bureau of Land Management

[WO-350-1540-01]

Extension of Approved Information Collection, OMB Number 1004–0009

AGENCY: Bureau of Land Management, Interior.

ACTION: Notice and request for comments.

SUMMARY: In accordance with the Paperwork Reduction Act of 1995, the Bureau of Land Management (BLM) is announcing its intention to request an extension of existing approval to collect certain information from applicants who wish to acquire a Land Use Authorization (form 2920–1) on public lands under the Federal Land Policy and Management Act (FLPMA) of 1976. The regulations at 43 CFR 2920 provide for non-Federal use of Bureau-administered land by means of lease or